Evaluation of prostaglandin biosynthetic activity in canine basilar artery following subarachnoid injection of blood.
Transformation of arachidonic acid into prostaglandins was investigated in the basilar artery by incubating sections of artery with carbon-14-labeled arachidonic acid. Thin-layer radiochromatography revealed that, in normal canine basilar arteries, 14C-arachidonic acid was transformed mainly to 6-keto-prostaglandin (PG)F1 alpha, a spontaneous metabolite of prostacyclin (PGI2). Among other prostaglandins, only a small amount of PGF2 alpha was detected, whereas PGD2, PGE2, and thromboxane B2 were not. Arteries removed on Days 3 and 8 after subarachnoid blood injection showed a prostaglandin synthesis profile similar to that in the normal cerebral artery. In borate-buffered saline  (0.1M borate buffer, pH 9.0/0.15M NaCl = 1:9, vol/vol), canine basilar artery produced a PGI2-like substance that inhibited adenosine diphosphate (ADP)-induced platelet aggregation. Its anti-aggregatory activity was completely abolished by acidification. Aspirin likewise inhibited production of the anti-aggregatory substance. From these results, it was concluded that the anti-aggregatory activity was due solely to the production of PGI2 by the arterial specimen. Based on the above results, PGI2 biosynthetic activity in the cerebral artery exposed to subarachnoid blood injection was bioassayed by measuring the inhibitory activity of the incubation product upon ADP-induced platelet aggregation following incubation of the arteries in borate-buffered saline for 5 to 30 minutes at 20 degrees C, using synthetic PGI2-Na as a standard. The synthetic activity of PGI2 in the artery exposed to subarachnoid blood injection had diminished remarkably by Days 3 and 8. This diminution of PGI2 synthesis in the cerebral artery may be involved in the pathogenesis of cerebral vasospasm.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001488:Basilar Artery / Q000378:metabolism*; D001769:Blood; D015815:Cell Adhesion Molecules; D002449:Cell Aggregation / Q000187:drug effects; D004285:Dogs; D011464:Epoprostenol / Q000378:metabolism; D007267:Injections; D011453:Prostaglandins / Q000096:biosynthesis*; D011506:Proteins / Q000037:antagonists & inhibitors; D013345:Subarachnoid Hemorrhage / Q000503:physiopathology; D013346:Subarachnoid Space; D013997:Time Factors
D001095:Arachidonic Acids; D015815:Cell Adhesion Molecules; D011453:Prostaglandins; D011506:Proteins; C013065:cell aggregation factors; D016718:Arachidonic Acid; D011464:Epoprostenol